导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.93% | 3572/4762 |
| 近一周 | -1.36% | 2058/5451 |
| 近一月 | 2.12% | 249/5408 |
| 近一季 | 1.65% | 684/5218 |
| 近半年 | -1.66% | 1847/4907 |
| 近一年 | -5.40% | 3164/4387 |
| 近两年 | 31.82% | 2210/2950 |
| 近三年 | 23.10% | 1368/2249 |
| 成立以来 | 47.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.55% 4306/4961 |
-3.89% 3481/5312 |
- - |
- - |
| 2025 | 9.69% 2855/4813 |
-1.71% 2756/3635 |
8.38% 340/4076 |
-0.37% 3924/4524 |
3.35% 690/4813 |
| 2024 | 31.84% 91/3463 |
2.31% 798/2808 |
0.50% 593/3014 |
26.33% 270/3129 |
1.51% 1061/3463 |
| 2023 | -4.88% 700/2656 |
-1.10% 1852/2280 |
-0.35% 377/2385 |
4.94% 110/2515 |
-8.02% 2236/2655 |
| 2022 | -12.12% 271/2207 |
-5.15% 181/1919 |
-1.47% 1728/2016 |
-10.38% 395/2113 |
4.93% 501/2208 |
| 2021 | -7.34% 1035/1822 |
-1.56% 512/1255 |
-2.33% 1201/1330 |
-4.21% 691/1466 |
0.61% 1087/1822 |
| 2020 | 1.91% 928/1250 |
-14.25% 955/1028 |
5.02% 892/1067 |
9.03% 680/1164 |
3.80% 888/1184 |
| 2019 | 34.30% 406/1092 |
26.70% 382/754 |
-0.76% 286/804 |
-0.73% 610/850 |
7.59% 421/918 |
| 2018 | -18.53% 146/834 |
- - |
- - |
- - |
-7.86% 73/691 |
| 2017 | 19.06% 201/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发中证全指金融地产联接C VS. 长安沪深300非周期A(740101) |